AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18791486
Drug: Raloxifene plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene plus ossein-hydroxyapatite compound (RLX + OHC)
Trial: 18791486
Drug: Raloxifene plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene plus calcium carbonate (RLX + CC)
Trial: 16773412
Drug: Urinary NGAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary NGAL levels <200 ng/ml
Trial: 16773412
Drug: Urinary NGAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary NGAL levels >=200 ng/ml
Trial: 14672296
Drug: Energy supplement
RxNorm normalized name: Nutritional Supplement Oral Bar [PROTEIN FORTIFIED ENERGY SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy supplement
Trial: 8583618
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg allopurinol daily
Trial: 8583618
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg allopurinol daily
Trial: 1957753
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg, alternate day)
Trial: 7083769
Drug: Propranolol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (oral and intravenous)
Trial: 7083769
Drug: Propranolol absorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol absorption in untreated coeliac patients
Trial: 7083769
Drug: Propranolol absorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol absorption overall
Trial: 26332193
Drug: Heparin alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone, Bivalirudin alone, Heparin plus GPI, Bivalirudin plus GPI
Trial: 26332193
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment phase
Trial: 25179366
Drug: Intra-arterial treatment
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial treatment (IAT) including thrombolysis with alteplase or urokinase, mechanical treatment, or both.
Trial: 25179366
Drug: No intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: No intra-arterial treatment (no IAT).
Trial: 15339411
Drug: Xuezhikang Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang Capsule
Trial: 20473736
Drug: Polyene phosphatidylcholine
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyene phosphatidylcholine capsule
Trial: 16011059
Drug: Postoperative loco-regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative loco-regional radiation therapy
Trial: 7593899
Drug: morphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine plus midazolam (M)
Trial: 2405741
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) infusion at a dose of 30 ng.kg‐1.min‐1 for 7 days
Trial: 6994764
Drug: Guanfacine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (0.01 mg/kg)
Trial: 6994764
Drug: Guanfacine (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (0.02 mg/kg)
Trial: 6994764
Drug: Guanfacine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (0.04 mg/kg)
Trial: 6994764
Drug: Guanfacine (0.01,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (0.01, 0.02, 0.04 mg/kg)
Trial: 2253662
Drug: Ibopamine 400
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 400 mg
Trial: 25946916
Drug: Self-administered acupressure
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered acupressure intervention (5 sessions, 3 times a day for 2 weeks)
Trial: 23932793
Drug: Pill-placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill-placebo
Trial: 11831541
Drug: Fluconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (100 mg daily for 4 days)
Trial: 11831541
Drug: Rectal bromazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal bromazepam (3 mg)
Trial: 10348276
Drug: Radioactive iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radioactive iodine (131I) ablation doses ranging from less than 30 mCi to 100 mCi.
Trial: 8665549
Drug: Ketamine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (mean dose, 58 mg)
Trial: 8665549
Drug: Alfentanil (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (mean dose, 11 mg)
Trial: 2341121
Drug: Atropine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (1 mg intravenously)
Trial: 2341121
Drug: Cimetropium bromide
RxNorm normalized name: cimetropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetropium bromide (5 mg intravenously)
Trial: 31571633
Drug: RISUG (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RISUG (120 μl as bilateral vas intraluminal injection)
Trial: 18277222
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy skills training group (16 sessions, once-weekly)
Trial: 17135639
Drug: Docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel plus cyclophosphamide (TC) (75 and 600 mg/m2, respectively; n = 506)
Trial: 17135639
Drug: Doxorubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin plus cyclophosphamide (AC) (60 and 600 mg/m2, respectively; n = 510)
Trial: 8513849
Drug: Cilazapril 2.5
RxNorm normalized name: cilazapril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 2.5 mg plus Hydrochlorothiazide 12.5 mg
Trial: 3644367
Drug: Choice condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice condition (selected from three equally effective preparations)
Trial: 24843529
Drug: Exenatide 10
RxNorm normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 μg
Trial: 21961484
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg orally (positive control)
Trial: 21961484
Drug: Plasma insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma insulin
Trial: 12699262
Drug: Low-dose monophasic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose monophasic oral contraceptive continuously
Trial: 12699262
Drug: Progestins (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestins (oral, intramuscular, or IUD)
Trial: 12699262
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist with immediate add-back therapy
Trial: 12699262
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy postoperatively
Trial: 8613630
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide nasal spray (110 micro g in each nostril once daily)
Trial: 8613630
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide nasal spray
Trial: 8613630
Drug: Astemizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (10 mg once daily)
Trial: 1358234
Drug: Balsalazide 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide 4 g/day
Trial: 1358234
Drug: Balsalazide 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide 2 g/day
Trial: 3965343
Drug: Golytely lavage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golytely lavage (3‐4 L)
Trial: 3965343
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation (48‐h clear liquid diet, 240 ml of magnesium citrate and 'X‐Prep' senna derivative)
Trial: 22632574
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (Early-PN)
Trial: 31375142
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (Late-PN)
Trial: 29805085
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) using JCP droplets or HDM tablets
Trial: 20463579
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate
Trial: 20463579
Drug: Immediate-release oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release oral morphine sulfate
Trial: 20463579
Drug: Global Medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Global Medication Performance Scale
Trial: 18595975
Drug: Oral corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroid bursts (0, 1 to 4, and >=5 courses)
Trial: 18595975
Drug: Cumulative inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative inhaled corticosteroid use
Trial: 10510577
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) injection with concentrated PHKCV
Trial: 10510577
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) injection with concentrated PHKCV after boosting
Trial: 10510577
Drug: Five routine
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five routine doses of rabies vaccine
Trial: 10510577
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) two or three doses after i.d. 0.1 mL nonconcentrated PHKCV
Trial: 1436604
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of UDCA‐hemisuccinate orally twice a day for six months
Trial: 1436604
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of S‐adenosyl‐methionine (SAMe) twice a day for six months
Trial: 3548109
Drug: Conventional pancreatic
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pancreatic enzyme preparation (Pankreon 700; 3 X 3 dragees daily) with cimetidine (300 mg)
Trial: 3548109
Drug: New pH-sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New pH-sensitive enzyme preparation (Kreon; 3 X 6 capsules daily) comprising acid-protected granules
Trial: 3548109
Drug: Conventional pancreatic
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pancreatic enzyme preparation (Pankreon 700; 3 X 3 dragees daily) without cimetidine
Trial: 31384878
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (LD) group - 2.5 × 10^9 CFU
Trial: 31384878
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (HD) group - 1 × 10^10 CFU
Trial: 23740093
Drug: Dysfunction markers
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysfunction markers (comorbidity, medication consumption, doctor's visits, difficulties in activities of daily living)
Trial: 23330127
Drug: Carnosine added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnosine added to treatment protocol for chronic brain ischemia
Trial: 2967781
Drug: Tizanidine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine (4 mg three times daily) plus ibuprofen (400 mg three times daily)
Trial: 2967781
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus ibuprofen (400 mg three times daily)
Trial: 28177710
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of bioactive collagen peptides (BCP) per day for 12 weeks
Trial: 21906250
Drug: Implantable hemodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable hemodynamic monitoring (IHM) system used in treatment group
Trial: 11153617
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 150 mg/kg iv bolus over 15 mins and continuous infusion of 12.5 mg/kg/hr over 90 mins (n = 30)
Trial: 25393622
Drug: Tacrolimus/MMF/steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus/MMF/steroids
Trial: 25393622
Drug: Tacrolimus/MMF/steroids +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus/MMF/steroids + Rituximab
Trial: 20432107
Drug: National Youth
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: National Youth Anti‐Drug Media Campaign (NYADMC) awareness
Trial: 18953854
Drug: Metoprolol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (oral or intravenous) administered from 2 hours before surgery to 30 days after surgery, dosage adjusted according to blood pressure and heart rate.
Trial: 17273608
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg of spray fenoterol (n = 41)
Trial: 12966259
Drug: Combination AMI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination AMI 1%/KET 0.5%
Trial: 12966259
Drug: Combination cream
RxNorm normalized name: SUNSCREEN-35 PABA-FREE COMBINATION CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination cream (open-label phase)
Trial: 10100330
Drug: Intervention course
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention course (behavior change skills taught in weekly lectures and peer-led labs)
Trial: 8875970
Drug: Cholesterol lowering
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol lowering interventions (low-fat/low-cholesterol diet, partial ileal bypass surgery, pharmacologic agents such as bile resins, fibrates, niacin, and HMG-CoA reductase inhibitors)
Trial: 1395119
Drug: Diuretic (hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (hydrochlorothiazide 50 mg and amiloride 5 mg)
Trial: 14510041
Drug: High-structure, behaviorally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-structure, behaviorally oriented (HSB) treatment
Trial: 14510041
Drug: Low-structure, facilitative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-structure, facilitative (LSF) treatment
Trial: 11098028
Drug: Oral contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraception (group B)
Trial: 11098028
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment after second cycle
Trial: 8884859
Drug: Aprotinin (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (group A, n = 46) - 2 x 10(5) KIU before incision, 2 x 10(6) KIU in priming solution, 5 x 10(5) KIU/h during CPB
Trial: 1411667
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg controlled-release salbutamol (CRS)
Trial: 1411667
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg controlled-release salbutamol (CRS)
Trial: 2865721
Drug: Propofol for
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol for induction and maintenance of anaesthesia, 9.0 mg/kg/h for 30 min followed by 4.5 mg/kg/h supplemented with fentanyl
Trial: 28452866
Drug: Dopamine reuptake
RxNorm normalized name: Dopamine reuptake inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine reuptake inhibitor (methylphenidate)
Trial: 28452866
Drug: Norepinephrine reuptake
RxNorm normalized name: Norepinephrine reuptake inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine reuptake inhibitor (reboxetine)
Trial: 23907995
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg eteplirsen
Trial: 23907995
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg eteplirsen
Trial: 19219630
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no further local treatment)
Trial: 14628428
Drug: 5FU/Lev (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU/Lev (50 mg orally three times/day for 3 days, repeated every 2 weeks for 1 year)
Trial: 14628428
Drug: 5FU alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU alone (450 mg/m2 i.v. bolus daily for 5 days and then weekly for 48 weeks)
Trial: 11104315
Drug: Psychosocial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial treatment for anxious ADHD children
Trial: 11104315
Drug: Medication response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Medication response
Trial: 8247036
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of cisplatin (100 mg/m²) and cyclophosphamide (300 mg/m²)
Trial: 8247036
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of cisplatin (80 mg/m²) and cyclophosphamide (225 mg/m²)
Trial: 8247036
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of cisplatin and cyclophosphamide
Trial: 8247036
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of cisplatin and cyclophosphamide
Trial: 30420969
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus Oral Hypoglycemic Agents (OHAs)
Trial: 30420969
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus OHAs
Trial: 29944308
Drug: Monthly Sulphadoxine-Pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly Sulphadoxine-Pyrimethamine (SP)
Trial: 29944308
Drug: Daily Proguanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Proguanil
Trial: 18539666
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of triamcinolone acetonide, bupivacaine, and epinephrine
Trial: 18539666
Drug: Injection mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection mixture without triamcinolone (Control)
Trial: 12676261
Drug: Amifostine 500
RxNorm normalized name: amifostine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine 500 mg i.v. prior to each radiotherapy fraction
Trial: 11077135
Drug: L-arginine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (6 g/24 h for 3 days)
Trial: 1348663
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 275 mg (two capsules)
Trial: 1348663
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two identical capsules)
Trial: 6140355
Drug: Insulin-dependent diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetic women who later acquired other endocrine disease
Trial: 6140355
Drug: Insulin-dependent diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetic women without other endocrine disease
Trial: 31356450
Drug: Mindfulness-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based stress reduction (MBSR) plus treatment-as-usual (TAU)
Trial: 22529301
Drug: ALVAC‐HIV (vCP1521)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC‐HIV (vCP1521) and AIDSVAX B/E vaccine
Trial: 12427399
Drug: Intranasal estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal estradiol 300 microg/day (one spray delivery of 150 microg per nostril)
Trial: 7723351
Drug: Buflomedil 50
RxNorm normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buflomedil 50 mg
Trial: 7723351
Drug: Buflomedil 100
RxNorm normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buflomedil 100 mg
Trial: 7723351
Drug: Buflomedil 200
RxNorm normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buflomedil 200 mg